Key Takeaways Intuitive Surgical is aligning with the shift of procedures to ASCs and outpatient settings.ISRG sees ASCs as a long-term growth driver, supported by XiR systems and trained surgeons.Intuitive Surgical notes ASC growth, high utilization and suitable procedures for robotic efficiency.Intuitive Surgical (ISRG) is increasingly aligning its strategy with the ongoing migration of surgical procedures toward lower-cost care settings, particularly ambulatory surgery centers (ASCs). Management noted a ...

Core Insights - Intuitive Surgical (ISRG) is experiencing a decline in U.S. bariatric surgery volumes, attributed to the rapid adoption of GLP-1 weight-loss drugs, with six consecutive quarters of high single-digit declines [1][10] - Bariatric procedures now account for less than 3% of U.S. da Vinci procedures, and the decline shows no signs of stabilization [2][10] - Despite the challenges in bariatric surgery, Intuitive Surgical is seeing growth in other areas, particularly benign general surgery, which includes procedures like cholecystectomy and hernia repair [3][10] Bariatric Surgery Impact - The ongoing decline in bariatric surgery volumes is linked to mixed patient behaviors regarding GLP-1 therapies, with some patients discontinuing due to costs or side effects [2] - Surgeons report uncertainty in predicting when bariatric procedure volumes may stabilize, indicating a challenging environment for the company [2] Growth in Other Areas - Intuitive Surgical is offsetting the decline in bariatric procedures with strong growth in benign general surgery, which is supported by the adoption of the da Vinci 5 platform that enhances efficiency and utilization rates [3][4] - International markets are also contributing positively, with general surgery and other procedures growing between 26% to 39% year-over-year outside the U.S. [5] Competitive Landscape - Other medical-device companies, such as Medtronic and Teleflex, are similarly affected by the rise of GLP-1 drugs impacting bariatric procedures, but they view this as a near-term challenge rather than a complete replacement of surgical options [7][10] - Medtronic is focusing on faster-growing segments to mitigate the impact of declining bariatric volumes, with significant growth in cardiac ablation and other areas [9] Financial Performance - Intuitive Surgical's shares have increased by 6.5% year-to-date, outperforming the industry average of 2% [13] - The company has a forward price-to-earnings ratio of 58.42, which is above the industry average but lower than its five-year median of 71.54 [14] - The Zacks Consensus Estimate indicates a projected earnings growth of 17.3% for 2025 compared to the previous year [15]